Both hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are characterized by thrombotic microangiopathy (TMA), affecting mainly the kidney and brain, respectively. Diagnosis ...

TSP-1 reduced C3 and C5 cleavage and formation of the membrane attack complex, attenuating complement-mediated injury in AAV models. Complement activation is a relevant driver in the pathomechanisms ...

Atypical hemolytic–uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain normal levels ...

An 18-month-old boy was admitted with a fourth relapse of congenital atypical hemolytic–uremic syndrome. He was born at 34 weeks' gestation, and thrombotic microangiopathy developed within the first 8 ...

Left untreated, PNH could cause death in about half of patients within 10 years of diagnosis. The primary cause of PNH-related mortality is thromboembolic events. A host of anti-complement strategies, ...

(Nanowerk Spotlight) Any drug intended for systemic administration and all medical devices which will contact blood (e.g. oxygenators, tubing, catheters, artificial hearts) must undergo thorough ...

"Our previous work showed that SARS-CoV-2 spike proteins lead to complement dysregulation by binding heparan sulfate and disrupting complement factor H…This doesn’t happen on red cells because red ...

Please provide your email address to receive an email when new articles are posted on . The monoclonal antibody eculizumab has received accelerated approval from the FDA for the treatment of pediatric ...